Search

Proposed Federal Workplace Drug Testing Guidelines

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a proposed rule to update federal workplace drug testing guidelines. This consultation seeks public comment on the proposed changes to these guidelines.

HHS Drug Testing Panel Guidelines

The Department of Health and Human Services (HHS) has issued updated guidelines for authorized drug testing panels used in federal workplace drug testing programs. The current drug testing panels for urine and oral fluid, along with the required nomenclature for laboratory and Medical Review Officer Reports, remain in effect as of July 7, 2025, with minor edits to footnotes for clarity.

HHS Modifies Privacy Act System of Records

The Department of Health and Human Services (HHS) is modifying a Privacy Act system of records, System No. 09-90-0052, to include reporting on substance use disorder patient records. The comment period for these modifications ends on March 19, 2026.

HHS Opioid Use Disorder Medications Correction

The Department of Health and Human Services (HHS) is issuing a correcting amendment to the final rule on Medications for the Treatment of Opioid Use Disorder. This document corrects outdated references within the regulation, with an effective date of February 23, 2026.

HHS Proposes Rescinding LGBTQI+ Children Placement Rule

The Administration for Children and Families (ACF) proposes to remove a final rule concerning designated placement requirements for LGBTQI+ children in foster care. This action follows a court decision vacating the rule, which the court found exceeded HHS's statutory authority. The public comment period for this proposed rescission ends April 6, 2026.

FDA Natural Family Planning Review

The FDA has posted a review concerning Natural Family Planning methods. This document provides updated information and guidance related to these methods.

FDA Acknowledgment Letter to Special FX Rentals

The FDA's Center for Devices and Radiological Health (CDRH) has issued an acknowledgment letter to Special FX Rentals. This notice confirms receipt of documentation and does not indicate approval or disapproval of any submissions.

FDA Variance Approval Letter

The FDA has issued a variance approval letter to Richard Lathrop, authored by CDRH. The letter, which contains restricted personally identifiable information, has been redacted and is available for download.

FDA Approves Labeling for RS, ANDA 202682

The U.S. Food and Drug Administration (FDA) has approved labeling for RS, as indicated by ANDA 202682. This approval was posted on March 13, 2026, and pertains to specific drug product labeling.

FDA Acknowledgment Letter to Athyna Pharma

The FDA's Center for Drug Evaluation and Research (CDER) has issued an acknowledgment letter to Athyna Pharma, LLC. This notice confirms receipt of a submission from the company.